Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by RPINVESTOR1on Mar 26, 2024 7:58am
51 Views
Post# 35952451

RE:RE:RE:The Take-Over

RE:RE:RE:The Take-OverHi Ingiboy:-

Even if we all owned the same number of shares as before, in order to receive 92% of the revenue, Andrew Schutte would have to have some type of 'special' shares himself! 

Yes they did introduce a 'poison pill' some years ago. Talk about optimism!

If Andrew Schutte thinks he can pull this robbery off, what is the incentive for him to try to find a solution to the issues Replicel is facing before the vote? We do not even know if he has spoken with 'interested potential partners!'

Turning the tables, does anyone really believe that Andrew Schutte would accept an 'offer to purchase' like this from any other Replicel shareholder?

It amazes me that we went from a professional presentation on the Company moving forward at the September AGM to complete silence for 6 months (with the exception of the arbitration decision news release) to this! Was this the CEO's plan B all of the time?
  

  
<< Previous
Bullboard Posts
Next >>